Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Tuebingen – page 22

612 clinical trials in Tuebingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Tuebingen at a glance
612
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

612 trials in Tuebingen

Open in trial search

Breast cancer+2

Recruiting

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:WSG Women's Cancer Study Group GmbH

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Neoplasm

Recruiting

Study on Long-Term Safety of BI 907828 for Patients with Solid Tumors Who Previously Participated in a Study with This Medicine

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Oral Propranolol for Preventing Severe Retinopathy in Premature Infants

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Propranolol Hydrochloride
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Long-term safety and effectiveness study of vatiquinone (oral capsules) in patients with Friedreich ataxia who have previously received this treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Vatiquinone
  • Sponsor:PTC Therapeutics Inc.

Study on the Effects of Filgotinib for Children and Teenagers with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Dermatitis atopic

Not yet recruiting

Testing GIA632 compared to placebo in adults with moderate to severe atopic dermatitis to measure effectiveness and safety

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not yet recruiting

Study of IMG-007 injection to treat moderate to severe atopic dermatitis in adults

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:IMG-007
  • Sponsor:Inmagene LLC

Non-small cell lung cancer

Not yet recruiting

Pembrolizumab alone versus pembrolizumab with chemotherapy drug combination in women with advanced non‑small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Tuebingen

What the registry says about research in the country

01 Neurology and Stroke Care

In Tübingen, clinical research in nervous system diseases focuses on improving outcomes for people with acute ischemic stroke, Parkinson disease, and multiple system atrophy. These studies are testing new treatment strategies and better ways to restore function after neurological injury or slow disease progression.

  • Acute ischemic stroke with incomplete reperfusion
  • Stroke in patients with recent direct oral anticoagulant use
  • Parkinson disease and multiple system atrophy
  • New approaches to treatment effectiveness and recovery

The research also includes imaging and diagnostic work, reflecting a broader effort to refine how brain disorders are detected and managed.

02 Oncology and Hematology

Clinical trials in neoplasms and hemic and lymphatic diseases are exploring targeted and immune-based treatments for a wide range of cancers, including renal cell carcinoma, follicular lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The aim is to improve survival, control relapse, and expand options for hard-to-treat disease.

  • Metastatic renal cell carcinoma
  • Relapsed and refractory follicular lymphoma
  • Chronic lymphocytic leukemia and Philadelphia chromosome-positive B-ALL
  • Evaluation of combination therapies and immune-based cancer control

Research in this area also covers solid tumors such as glioblastoma, colorectal cancer, melanoma, sarcoma, and neuroblastoma.

03 Pain, Anesthesia, and Critical Care

Studies in anesthesia and analgesia and pathological conditions are addressing chronic and acute pain, sedation, and treatment support for severely ill patients. Several trials are evaluating whether new approaches can ease persistent pain while improving safety in complex hospital settings.

  • Chronic back pain and neuropathic pain syndromes
  • Critical illness with mechanical ventilation and intensive care support
  • Older critically ill patients receiving early sedation strategies
  • Testing symptom relief and treatment tolerability

This area highlights both comfort-focused care and the search for better outcomes in intensive care medicine.

04 Cardiovascular and Thromboembolic Research

Research in cardiovascular diseases is examining how to reduce stroke, bleeding, and other vascular complications in high-risk patients. Trials in the city are especially focused on prevention after heart procedures and in people with complex clotting or bleeding histories.

  • Aortic valve stenosis and care after transcatheter valve implantation
  • High-risk atrial fibrillation with prior intracranial hemorrhage
  • Risk reduction for stroke and systemic embolism
  • Personalized antithrombotic treatment strategies

These studies aim to make anticoagulation and antiplatelet treatment safer and more precise.

05 Respiratory and Neonatal Medicine

Trials in respiratory tract diseases are centered on premature infants and lung development, with an emphasis on early support that may improve long-term breathing outcomes. The research also extends to critically ill newborns needing specialized care shortly after birth.

  • Respiratory distress syndrome in preterm infants
  • Prophylactic surfactant use in very premature babies
  • Long-term lung function in childhood
  • Improving neonatal respiratory support

These studies reflect a strong interest in protecting fragile infants during the earliest stages of life.

06 Eye and Skin Disease Studies

Clinical research in eye diseases and skin and connective tissue diseases is evaluating treatments for progressive vision loss and persistent inflammatory skin conditions. The goal is to slow disease-related damage and improve day-to-day quality of life.

  • Non-foveal geographic atrophy in age-related macular degeneration
  • Prurigo nodularis
  • Basal cell carcinoma and cutaneous squamous cell carcinoma
  • Testing new therapies for lesion control and symptom relief

There is also interest in treatment approaches for difficult-to-manage skin cancers and chronic itch.

07 Kidney, Urinary, and Prostate Cancer Research

Studies in male urogenital diseases are focusing on cancers of the kidney, urinary tract, and prostate. These trials are evaluating whether newer treatments can better control tumor growth and preserve organ function.

  • Metastatic renal cell carcinoma
  • Low-grade upper tract urothelial cancer
  • Metastatic hormone-sensitive prostate cancer
  • Improving cancer control and treatment effectiveness

Some work also looks at protecting renal function, especially in patients facing additional medical risks.

08 Pediatric Oncology

Research in pediatric cancer is addressing some of the most challenging childhood tumors, including high-risk neuroblastoma and childhood renal tumors. These studies are designed to improve response rates and long-term event-free survival in young patients.

  • High-risk neuroblastoma
  • Stage IV childhood renal tumor
  • Response after treatment for advanced disease
  • Testing intensified and combined treatment strategies

This area includes efforts to strengthen treatment for children with metastatic or relapsed disease.

09 Immune and Transplant-Related Diseases

Trials in immune system diseases are investigating ways to manage overactive immune responses and complications after transplantation. The main focus is on improving disease control while reducing treatment burden and side effects.

  • Chronic graft versus host disease
  • Therapies that modulate immune activity
  • Supportive care for immune-mediated complications
  • Evaluation of treatment benefit and tolerability

These studies are especially relevant for patients needing long-term immune regulation after intensive therapy.

10 Psychiatry, Psychology, and Pediatric Behavioral Health

In the field of mental disorders, investigators are exploring safer and more effective ways to support children and adolescents treated with antipsychotic medicines. The research also includes conditions such as autism spectrum disorder, showing a broad interest in developmental and behavioral health.

  • Medication monitoring for risperidone and aripiprazole
  • Weight gain and treatment tolerability in young patients
  • Autism spectrum disorder
  • Improving safety in long-term psychiatric care

These studies aim to make treatment more personalized for younger patients.

11 Diagnostic and Translational Imaging

Some trials in Tübingen concentrate on diagnosis and imaging tools, aiming to improve how disease processes are detected and monitored. This includes work in neurological and cancer-related settings where earlier or more precise identification could support better treatment decisions.

  • Diagnostic imaging for brain and movement disorders
  • Assessment of disease activity in cancer and neurology
  • Evaluating new tools for clinical detection
  • Supporting more accurate treatment planning

These studies help bridge laboratory research and practical patient care.

12 Specialized Therapeutic Techniques and Equipment

Research in therapeutics and related clinical techniques includes novel treatment approaches that combine device-based care, drug therapy, and procedure-guided interventions. The studies often target complex diseases where standard options are limited.

  • Stroke treatment and clot removal support
  • Image-guided and personalized treatment strategies
  • Procedure-based care in oncology and cardiovascular medicine
  • Testing whether new therapeutic combinations improve outcomes

This reflects a strong interest in practical innovations that can be integrated into routine care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.